Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis
Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing 100010, Peoples R China..
Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing 100010, Peoples R China.;Beijing Univ Chinese Med, Beijing 100029, Peoples R China..
Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing 100010, Peoples R China.;Beijing Univ Chinese Med, Beijing 100029, Peoples R China..
Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing 100010, Peoples R China.;Beijing Univ Chinese Med, Beijing 100029, Peoples R China..
Show others and affiliations
2016 (English)In: Evidence-based Complementary and Alternative Medicine, ISSN 1741-427X, E-ISSN 1741-4288, 3281968Article, review/survey (Refereed) Published
Resource type
Text
Abstract [en]

Chinese herbal medicine (CHM) has been increasingly employed during therapy for breast cancer, but its efficacy remains a matter of debate. This systematic review examined randomized controlled trials to provide a critical evaluation of this treatment. The results demonstrated that the combined use of CHM with chemotherapy may improve the immediate tumor response and reduce chemotherapy-associated adverse events. Our findings highlight the poor quality of Chinese studies, and additional well-designed randomized controlled trials addressing the role of CHM are warranted. The lack of molecular-based evidence for CHM and Zheng has resulted in a limited understanding and acceptance of CHM and traditional Chinese medicine in Western countries. We believe that researchers should immediately explore a CHM-based cure, and CHM should be applied to routine care as soon as conclusive data are available.

Place, publisher, year, edition, pages
2016. 3281968
National Category
Cancer and Oncology Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-299294DOI: 10.1155/2016/3281968ISI: 000374849800001OAI: oai:DiVA.org:uu-299294DiVA: diva2:949177
Available from: 2016-07-18 Created: 2016-07-18 Last updated: 2017-11-28Bibliographically approved

Open Access in DiVA

fulltext(2154 kB)151 downloads
File information
File name FULLTEXT01.pdfFile size 2154 kBChecksum SHA-512
770567ef495588dc536004fc5b0970d4643fa718e77d851aacae4f34a7349c86b19044a316b2699b5c640e06c2ce6e55b2c1715b3dac81ef98fb9e47c1048379
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Li, Jin-Ping
By organisation
Department of Medical Biochemistry and Microbiology
In the same journal
Evidence-based Complementary and Alternative Medicine
Cancer and OncologyPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 151 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 471 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf